Jeanelle King Javier de la Cruz Jose Lutzky
10.1186/s40425-017-0224-7
J Immunother Cancer
2017 Mar 21;5:19.
CC BY
https://pubmed.ncbi.nlm.nih.gov/28344807/
CTLA-4 Antigen / antagonists & inhibitors Ipilimumab / adverse effects Melanoma / drug therapy Purpura, Thrombotic Thrombocytopenic / pathology
CTLA-4 Antigen / antagonists & inhibitors Ipilimumab / adverse effects Melanoma / drug therapy Purpura, Thrombotic Thrombocytopenic / pathology Case Reports Aged CTLA-4 Antigen / immunology CTLA-4 Antigen / therapeutic use Drug-Related Side Effects and Adverse Reactions / immunology Drug-Related Side Effects and Adverse Reactions / pathology Female Humans Immune System Diseases / chemically induced Immune System Diseases / pathology Ipilimumab / administration & dosage Melanoma / complications Melanoma / immunology Melanoma / pathology Purpura, Thrombotic Thrombocytopenic / chemically induced Purpura, Thrombotic Thrombocytopenic / diagnosis T-Lymphocytes / drug effects T-Lymphocytes / immunology T-Lymphocytes, Cytotoxic / drug effects CTLA-4 Antigen Ipilimumab
PMC5360069
28344807
Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)
2017